04:06:17 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Essa Pharma Inc
Symbol EPI
Shares Issued 18,118,779
Close 2015-03-05 C$ 5.40
Market Cap C$ 97,841,407
Recent Sedar Documents

Essa appoints Berger to board

2015-03-05 18:45 ET - News Release

Mr. Bob Rieder reports

ESSA PHARMA INC. ANNOUNCES APPOINTMENT OF NEW DIRECTOR

Essa Pharma Inc. has appointed Franklin Berger to its board of directors. Mr. Berger's appointment as an independent director is effective immediately. A resident of New York, Mr. Berger's background includes advisory work with top-tier venture capital firms and international biopharmaceutical companies.

"We are delighted to have Franklin join our board," stated Richard Glickman, chairman of the Essa board of directors. "As an investor in Essa, he has a serious stake in our success. As a deeply experienced strategic adviser, he will bring an invaluable perspective to our strategy decisions."

Mr. Berger spent 12 years in sell-side equity research, most recently as managing director, U.S. equity research, at J.P. Morgan Securities Inc. from May, 1998, to March, 2003. During his five years at JPM, he was involved with the issuance of over $12-billion in biotechnology company equity or equity-linked securities. The majority of these transactions were book run and lead managed by the JPM biotech team. He was associated with several notable financings in the biotechnology sector, including the Genentech Inc. initial public offering and the first large Celgene Corp. financings, as well as financings of several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly traded biotechnology companies. Mr. Berger began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as director, equity research and senior biotechnology analyst.

Mr. Berger currently serves on the board of directors of three public biotechnology companies: Five Prime Therapeutics Inc., Immune Design Corp. and Bellus Health Inc. Previous public company board service included 11 years with Seattle Genetics Inc. and seven years with VaxGen Inc. and Aurinia Pharmaceuticals Inc. (previously Isotechnika Pharma Inc.), based in Canada. He also serves or has served on private biotech company boards of directors, including iTherX Pharma Inc., Caprion Proteomics Inc. (sold in July, 2012) and ViroChem Pharma Inc., which was purchased by Vertex Pharmaceuticals Inc. for $400-million in 2009. Mr. Berger has led multiple merger and acquisition analyses resulting in greater than $1-billion in transaction value.

The company previously announced on Jan. 27, 2015, the commencement of trading as a public company on the TSX Venture Exchange and the filing with the Securities and Exchange Commission on Feb. 25, 2015, of a registration statement on Form 20-F to register its common shares under the U.S. Securities Exchange Act of 1934, as amended. This filing is an initial step in the process of seeking a listing on an exchange based in the United States.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.